Thomas Schinecker, Roche CEO (Georgios Kefalas/EPA-EFE/Shutterstock )
October 19, 2023 06:22 AM EDTUpdated 06:33 AM
Pharma

Roche makes four pipeline changes on back of tri­al fail­ures, but sees path ahead for three ther­a­pies

Ayisha Sharma

News Reporter

Roche is re­work­ing its plans for a quar­tet of clin­i­cal pro­grams span­ning dif­fer­ent ther­a­peu­tic ar­eas and stages of de­vel­op­ment, but it may not be the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times